Europe Cancer Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Europe Cancer Biomarkers Market Analysis

The European Cancer Biomarkers Market is expected to register a CAGR of nearly 11.6% during the forecast period with a revenue of approximately USD 4,008 million in 2020, and it is expected to reach USD 7,764 million by 2026. Certain factors driving the growth of the market include the increased burden of cancer and the increasing focus on innovative drug development.

With the rising of the COVID-19, several companies increased their focus on the development of drugs or vaccines for COVID-19, showing a negative impact on interventional and other cancer biomarker-related clinical trials, which have been stopped as a result of the COVID-19 virus situation across the world. It is observed that it will have a negative impact for a short period of time. The companies such as Pfizer, Eli Lilly, and Bristol-Myers Squibb have also announced that they had halted the new clinical trials as a result of COVID-19. As per Pfizer's announcement, in late March 2020, the company paused the recruitment portion of certain global interventional clinical trial studies to avoid adding to the demands on the healthcare system during the peak of the crisis.

As per the estimates of the Globocan 2020, there were 467,965 new cases of cancer in France, and there had been 185,621 deaths due to it. According to the Fondation de France, cancer affects over 350,000 people every year and kills close to 150,000, representing roughly 1/3 of total deaths. Due to this high prevalence of cancer, increasing efforts are being made in R&D for the development of novel cancer therapeutics and diagnostics.

Thus, cancer biomarker is found playing a pivotal role in risk assessment and early diagnosis. Biomarkers, particularly those associated with genetic factors, offer a quantitative way to determine when individuals are predisposed to some form of cancer. These biomarkers have been developed for almost all cancers with a high prevalence rate. Some of the examples for such biomarkers are mutation on KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver and pancreatic cancer, and BRCA1 and BRCA2 for breast and ovarian cancer.

Biomarker-based early detection enables sensitive and cost-effective testing, which is expected to reduce cancer mortality. The biomarker’s potential to assess the risk precisely has helped in improving the adoption of the technology, which has led to market expansion.

Furthermore, in November 2019, Hitachi and Centre Léon Bérard cancer center in France promoted R&D aimed at improving the efficiency of diagnosis and treatment of cancer and established a new research laboratory called Hitachi Lyon Lab. The research also includes the identification of biomarkers exploiting genomic data in the context of resistance, which may allow predicting responses and prognoses upon radiation treatment. Hence, the high burden of cancer and increasing R&D activities are expected to boost the overall growth of the market.

Europe Cancer Biomarkers Industry Segments

As per the scope of the report, biomarkers are chemical, physical, or biological parameters, which can be used to indicate disease states. Oncology biomarkers offer high-speed, non-invasive cancer diagnoses, and enhance cancer detection and screening. The European cancer biomarkers market is segmented by disease (prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer, and other diseases), type (protein biomarkers, genetic biomarkers, and other types), and profiling technology (omics technology, imaging technology, immunoassays, and cytogenetics). The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Europe Cancer Biomarkers Market Trends

This section covers the major market trends shaping the Europe Cancer Biomarkers Market according to our research experts:

The Lung Cancer Segment is Expected to Hold a Major Market Share in the European Cancer Biomarkers Market

Lung cancer is caused by the uncontrolled growth of abnormal cells that multiply in one lung or both lungs. Although it can affect people who never smoked, people who smoke have the highest risk of lung cancer. The risk of lung cancer increases with the duration and number of cigarettes that the patient smoked. Other risk factors include occupational or environmental exposure to secondhand smoke, asbestos, certain metals, some organic chemicals, radiation, air pollution, and diesel exhaust.

With the rising cancer cases, there are millions of people that are being infected with COVID-19 around the globe. Since the focus of healthcare facilities was shifted to COVID-19, cancer patients' treatment was restricted for a certain period, followed by cancer biomarker-related clinical trials were being halted for a less period of time that showed a slight negative impact on the overall market.

According to the estimates of Globocan 2020, there were 457,960 new cancer cases in the United Kingdom, while prostate, breast, lung, colon, and skin cancer are the most common types of cancer detected in the United Kingdom.​ Based on the same estimates, there were 415,269 new cases of cancer in Italy and about 174,759 deaths.​ Therefore, owing to the rising number of cases of cancer, the cancer biomarkers market in Europe is expected to record substantial growth over the forecast period.

Some of the leading biomarkers for lung cancer include CYFRA 21-1, Plasma Kallikrein (KLKB1), Serum Amyloid A (SAA), Haptoglobin β Chain (Hp β), Complement Component 9 (C9), Endoglin (CD105), Peroxiredoxin 1 (PRX1), and Pro-gastrin-releasing Peptide (proGRP). As most of the aforementioned biomarkers are commercially available, the intensity of competition is already high in this segment. Therefore, the early diagnosis, coupled with the rising level of awareness among people, may lead to the healthy growth of the market studied.

To understand key trends, Download Sample Report